ImaRx buys Abbokinase

Biopharmaceutical firm ImaRx has purchased the thrombolytic drug Abbokinase, the trade name for urokinase.

The acquisition complements ImaRx's existing development programs, which include recombinant urokinase and recombinant pro-urokinase, said president and CEO Dr. Evan Unger. Abbokinase, which has been commercialized for more than 20 years, is approved for the lysis of acute massive pulmonary embolism.

By AuntMinnie.com staff writers
May 9, 2006

Related Reading

ImaRx adds VP, September 8, 2005

ImaRx receives $1.1 million grant, August 2, 2005

ImaRx's SonoLysis begins phase I/II PAOD trial, April 12, 2005

ImaRx initiates SonoLysis phase II stroke trial, April 5, 2005

ImaRx raises $7 million, March 10, 2005

Copyright © 2006 AuntMinnie.com

Page 1 of 509
Next Page